Pharmacokinetics of the major metabolites of D-penicillamine in patients with rheumatoid arthritis.
G Carruthers, M Harth, D Freeman, D Weir, R Rothwell, M Butler
Index: Clin. Invest. Med. 7(1) , 35-40, (1984)
Full Text: HTML
Abstract
The pharmacokinetic disposition of D-penicillamine and its major metabolites, penicillamine cysteine disulfide ( PSSC ) and penicillamine disulfide ( PSSP ) has been studied in eight patients with rheumatoid arthritis. Plasma concentrations of D-penicillamine, PSSP and PSSC displayed similar characteristics in terms of times to maximum concentrations and biphasic elimination from plasma. Initial t1/2 (alpha) phase ranged from 0.86 to 4.41 h for parent drug and 0.81 to 4.41 h for metabolites. Final t1/2 (beta phase) ranged from 3.4 to 9.45 h for D-penicillamine and 5.62 to 21.7 h for the metabolites. Total drug and metabolites detected in urine accounted for 12.0 to 48.7% of oral drug.
Related Compounds
Related Articles:
1987-07-01
[Clin. Chem. 33(7) , 1302-3, (1987)]
[J. Chromatogr. A. 491(2) , 341-54, (1989)]
Methods for assaying D-penicillamine in a clinical setting.
1984-01-01
[Clin. Invest. Med. 7(1) , 31-4, (1984)]
1988-01-01
[Drug Metabol. Drug Interact. 6(3-4) , 439-46, (1988)]
[J. Chromatogr. A. 318(2) , 404-7, (1985)]